Maddi Hebebrand, MC, Associate Editor

James Del Rosso, DO, discusses diagnosis and treatment of mastocytosis and inflammatory conditions.

AbbVie seeks FDA and EMA approval for upadacitinib, a potential breakthrough systemic treatment for non-segmental vitiligo in adults and adolescents.

The new hub for dermatology NPs and PAs offers education, community, and resources to enhance patient care and professional growth.

Fractional CO₂ laser treatment effectively reduces acne scars in Middle Eastern patients, balancing safety and efficacy for darker skin types.

Explore the long-term efficacy of biologics for HS, highlighting bimekizumab's superior outcomes in managing this chronic condition.

Arcutis reveals promising phase 2 results for roflumilast cream in infants with AD, highlighting safety and potential efficacy.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Kyowa Kirin takes full control of rocatinlimab, aiming to address unmet needs in atopic dermatitis while ensuring continuity in clinical trials.

Explore the top headlines of the month, including insights on regulatory updates, expert pearls, and more.

A phase 2 trial reveals soficitinib's potential to significantly improve symptoms and quality of life in patients with moderate to severe AD.

Dermatology Times is recapping our exclusive expert interviews from the month of January.

Explore the nuanced experiences of drainage in hidradenitis suppurativa (HS), revealing its profound physical and psychological impacts on patients' lives.

James Del Rosso, DO, discusses innovative therapies for chronic hand eczema (CHE), chronic spontaneous urticaria (CSU), and vitiligo.

Explore the nuances of off-label dermatology therapies, emphasizing evidence-based practices, patient communication, and ethical considerations for optimal care.

Ritlecitinib shows promising facial repigmentation in vitiligo patients, with consistent efficacy across diverse demographics in a phase 2b study.

Litifilimab shows significant efficacy in improving skin outcomes for CLE, as demonstrated in the phase 2 LILAC study.

Aclaris Therapeutics' ATI-2138 shows promising rapid hair regrowth in severe alopecia areata models, highlighting its potential as a novel treatment option.

Discover essential career insights for early-career NP/PAs in dermatology, focusing on skill mastery, mentorship, and professional growth strategies.

Bitopertin shows promise as a disease-modifying therapy for erythropoietic protoporphyria, significantly reducing PPIX levels and improving patient outcomes.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Explore the transformative role of AI in dermatology with Nawar Shara, PhD, focusing on personalized skin care and patient safety.

Belimumab shows significant long-term benefits for cutaneous lupus erythematosus, improving skin symptoms and maintaining efficacy.

Amlitelimab shows promise as a long-term therapy for atopic dermatitis (AD), offering effective results and favorable safety in recent clinical trials.

Switching from dupilumab to upadacitinib significantly improves skin clearance and itch in patients with moderate to severe atopic dermatitis (AD).

The 2025 Inflammatory Skin Disease Summit (ISDS) unveils innovative therapies and immune profiling strategies, transforming the landscape of dermatological care.

James Del Rosso, DO, discusses innovative topical therapies for dermatologic conditions.

Obagi Medical's ALOHA Program launches Obagi saypha MagIQ, pioneering real-world evaluation of a new hyaluronic acid filler.

Recent research shows the long-term benefits and safety of low-level laser therapy for androgenetic alopecia.